Qing-Yu Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Qing-Yu Zhang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Chao Zhang
Department of Gastroenterology, Tianjin Medical University General Hospital, Tianjin 300052, China
1 shared publicationHui Liu
Department of Gastroenterology, Affiliated Hospital of North China University of Science and Technology, Tangshan, Hebei 063000, China
1 shared publicationLi-Wei Jing
National Institute of Development and Strategy, Renmin University of China, Beijing 100872, China
1 shared publicationQiu-Meng Zhang
Department of Gastroenterology, Affiliated Hospital of North China University of Science and Technology, Tangshan, Hebei 063000, China
1 shared publicationZhi-Ting Li
Department of Gastroenterology, Affiliated Hospital of North China University of Science and Technology, Tangshan, Hebei 063000, China
1 shared publicationZi-Wei Chang
Department of Gastroenterology, Affiliated Hospital of North China University of Science and Technology, Tangshan, Hebei 063000, China
1 shared publication
Latest Publications
- Open Access
- 2 May 2019
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 39 (5)
Identification of a prognostic 28-gene expression signature for gastric cancer with lymphatic metastasis
Gastric cancer (GC) patients have high mortality due to late-stage diagnosis, which is closely associated with lymph node metastasis. Exploring the molecular mechanisms of lymphatic metastasis may inform the research into early diagnostics of GC. In the present study, we obtained RNA-Seq data from The Cancer Genome Altas and used Limma package to identify differentially expressed genes (DEGs) between lymphatic metastases and non-lymphatic metastases in GC tissues. Then, we used an elastic net-regularized COX proportional hazard model for gene selection from the DEGs and constructed a regression model composed of 28-gene signatures. Furthermore, we assessed the prognostic performance of the 28-gene signature by analyzing the receive operating characteristic curves. In addition, we selected the gene PELI2 amongst 28 genes and assessed the roles of this gene in GC cells. The good prognostic performance of the 28-gene signature was confirmed in the testing set, which was also validated by GSE66229 dataset. In addition, the biological experiments showed that PELI2 could promote the growth and metastasis of GC cells by regulating vascular endothelial growth factor C. Our study indicates that the identified 28-gene signature could be considered as a sensitive predictive tool for lymphatic metastasis in GC.
- 2 May 2019
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 39 (5)
Open AccessIdentification of a prognostic 28-gene expression signature for gastric cancer with lymphatic metastasis
Gastric cancer (GC) patients have high mortality due to late-stage diagnosis, which is closely associated with lymph node metastasis. Exploring the molecular mechanisms of lymphatic metastasis may inform the research into early diagnostics of GC. In the present study, we obtained RNA-Seq data from The Cancer Genome Altas and used Limma package to identify differentially expressed genes (DEGs) between lymphatic metastases and non-lymphatic metastases in GC tissues. Then, we used an elastic net-regularized COX proportional hazard model for gene selection from the DEGs and constructed a regression model composed of 28-gene signatures. Furthermore, we assessed the prognostic performance of the 28-gene signature by analyzing the receive operating characteristic curves. In addition, we selected the gene PELI2 amongst 28 genes and assessed the roles of this gene in GC cells. The good prognostic performance of the 28-gene signature was confirmed in the testing set, which was also validated by GSE66229 dataset. In addition, the biological experiments showed that PELI2 could promote the growth and metastasis of GC cells by regulating vascular endothelial growth factor C. Our study indicates that the identified 28-gene signature could be considered as a sensitive predictive tool for lymphatic metastasis in GC.